Back to top
more

Bausch Health Cos Inc. (BHC)

(Delayed Data from NYSE)

$28.08 USD

28.08
2,055,099

+0.32 (1.15%)

Updated May 7, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (175 out of 254)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.

Bausch Health (BHC) Beats Q1 Earnings Estimates

Bausch (BHC) delivered earnings and revenue surprises of 10.64% and -2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Why Is Bausch (BHC) Down 0.6% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates

Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.

Bausch Health (BHC) Q4 Earnings Beat Estimates

Bausch (BHC) delivered earnings and revenue surprises of 19.82% and -0.23%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Bausch Health (BHC) Ahead of Earnings?

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Bausch Health (BHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2020 results.

What's in Store for Zomedica (ZOM)This Earnings Season?

Zomedica (ZOM) may provide an update on Truforma commercialization progress when it reports fourth-quarter 2020 results.

What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?

Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.

TEVA Gears Up to Report Q4 Earnings: What's in the Cards?

On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.

Humana (HUM) to Report Q4 Earnings: What's in the Cards?

Humana's (HUM) fourth-quarter 2020 earnings might have endured escalating COVID-related expenses, partly offset by better revenues.

Bausch Health (BHC) Dry Eye Treatment Study Enrollment Complete

Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.

Why Is Bausch (BHC) Up 13.3% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.

Bausch (BHC) Begins Second Phase III Study on NOV03 for DED

Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.

Should Value Investors Consider Bausch Health (BHC) Now?

Let's see if Bausch Health (BHC) stock is a good choice for value-oriented investors right now from multiple angles.

Bausch's (BHC) Q3 Earnings and Revenues Surpass Estimates

Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.

Bausch Health (BHC) Q3 Earnings and Revenues Beat Estimates

Bausch (BHC) delivered earnings and revenue surprises of 28.43% and 1.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Bausch Health (BHC)

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Humana (HUM) Gears Up for Q3 Earnings: What Awaits the Stock?

Humana's (HUM) third-quarter 2020 results are likely to reflect elevated expenses and lower net investment income, partially offset by a growing membership base.

Universal Health (UHS) to Report Q3 Results: What to Expect

Universal Health's (UHS) third-quarter earnings results are likely to reflect depressed revenues and weak admissions.

Centene's (CNC) Q3 Earnings Improve Y/Y on High Revenues

Centene's (CNC) third-quarter results reflect higher revenues and managed care membership.

Anthem (ANTM) to Report Q3 Earnings: What's in the Cards?

Anthem's (ANTM) third-quarter earnings results are likely to reflect elevated costs and a softness in Commercial business line.